Q&A with Steven Lydeamore, CEO of Immuron Limited

Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream. https://www.immuron.com.au/assets/files/Profiled%20Company%20-%20Immuron%20-%20Summer%202023%20Issue.pdf

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.